Frederick, MD (PRWEB) November 28, 2013 Dr. Jon Rowley and Dr. Uplaksh Kumar, Co-Founders of RoosterBio, Inc., a newly formed biotech startup located in Frederick, are paving the way for even more innovation in the rapidly growing fields of Synthetic Biology and Regenerative Medicine. Synthetic Biology combines engineering principles with basic science to build biological products, including regenerative medicines and cellular therapies. Regenerative medicine is a broad definition for innovative medical therapies that will enable the body to repair, replace, restore and regenerate damaged or diseased cells, tissues and organs. Regenerative therapies that are in clinical trials today may enable repair of damaged heart muscle following heart attack, replacement of skin for burn victims, restoration of movement after spinal cord injury, regeneration of pancreatic tissue for insulin production in diabetics and provide new treatments for Parkinsons and Alzheimers diseases, to name just a few applications. While the potential of the field is promising, the pace of development has been slow. One main reason for this is that the living cells required for these therapies are cost-prohibitive and not supplied at volumes that support many research and product development efforts. RoosterBio will manufacture large quantities of standardized primary cells at high … Continue reading →

Amyloidosis - Different Forms and Treatement http://www.mslaw.edu In this excerpt from the Massachusetts School of Law's Educational Forum featuring Assistant Dean Diane Sullivan's journey through a ste... By: MSLawdotedu … Continue reading →

The most effective stroke treatments can only be given within the first few hours after a stroke has occurred. Once you are identified by ambulance or emergency personnel as someone who could be having a stroke, doctors will first need to know when your symptoms started. They will also need to make sure that your symptoms are not the result of bleeding inside your brain, as medical treatments for stroke can worsen bleeding. This information will help them determine what type of stroke you are having and what type of treatment you will need. There are two main types of stroke treatment: Intravenous TPA This is the first line of treatment against ischemic stroke. Tissue plasminogen activator or TPA is injected into the bloodstream through an intravenous line. TPA travels in the blood until it reaches the clot that is causing the stroke. Once there it begins to break up the clot until blood can flow past it toward the affected areas. What is TPA? It is important to note that intravenous TPA cannot be given to people who come into the emergency room more than three hours after the onset of their symptoms for two important reasons: First, three … Continue reading →

http://www.CLINICell.com "MCL TEAR alternative with PRP and Stem Cell Therapy" http://www.CLINICell.com PRP and Stem Cell Therapy or an MCL Tear offers the latest alternative treatments. Platelet Rich Plasma and Stem Cell treatments can be use... By: ClinicellTech … Continue reading →

Stem Cell Therapy Injections Stem Cell therapy, is one form of Comprehensive Prolotherapy available for arthritis treatment, and other chronic pain conditions at Caring Medical and Rehab... By: Rob C … Continue reading →

The neurodegenerative disorder Huntingtons disease (HD) is characterised by diminished muscle coordination, cognitive impairment and behavioural changes. It is a genetic disorder caused by the expansion of a CAG trinucleotide repeat in the gene encoding the huntingtin protein. This results in the degeneration of nerve cells, starting with those in the striatum of the brain. At present there is no treatment for this disease, nor any means to slow down its progression. Current therapies therefore focus on managing symptoms. Research is underway to determine whether stem cell therapies could reduce the neuropathological deficits brought on by HD and in doing so slow disease progression. A recent study published in Stem Cell Research & Therapy by Gary Dunbar from Central Michigan University, USA and colleagues, probes the potential of mesenchymal stem cells in treating a mouse model of HD. Immunohistochemical analysis of low passage (left) and high passage (right) umbilical cord mesenchymal stem cells (blue) transplanted into the striata of R6/2 mice. Stained for NeuN (red) and GFAP (green). Image source: Fink et al, Stem Cell Research & Therapy, 2013, 4:130 Dunbar and colleagues used the R6/2 mouse model of HD to test the efficacy of umbilical cord-derived mesenchymal stem cells … Continue reading →